5.7.2023 A9-0217/65

Amendment 65
Marc Botenga
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future (2022/2076(INI))

Motion for a resolution
Paragraph 275 b (new)

Motion for a resolution

Amendment

275b. Demands, in accordance with Regulation 1049/2001, the immediate publication of any and all SMS messages, or other messages, exchanged by the Commission President with any member of the management of any pharmaceutical companies that benefited from a vaccine purchase agreement with the Union;

Or. en
Amendment 66
Marc Botenga
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future (2022/2076(INI))

Motion for a resolution
Paragraph 300 a (new) (after subheading ‘Transparency’)

Motion for a resolution

Amendment

300a. Recommends that neither negotiators of contracts with pharmaceutical companies, nor experts consulted in the context of EU pharmaceutical policy or programmes or otherwise mobilised by the Member States or EU institutions, should have any financial or other interests that might be considered prejudicial to their independence, and that they should declare their financial and other interests, updating such declarations annually and whenever necessary in line with the procedures provided for at Member State or EU level; recommends that these declarations be made public; considers that experts should also disclose any facts of which they become aware during their participation in such procedures that might reasonably be expected to involve or give rise to a conflict of interest;

Or. en
5.7.2023

Amendment 67
Marc Botenga
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future (2022/2076(INI))

Motion for a resolution
Paragraph 556 a (new) (after subheading ‘Prevention capacity’)

Motion for a resolution

Amendment

556a. Demands that austerity instruments such as the Stability and Growth Pact and the European Semester, which have been used to pressure the Member States into cutting their public healthcare spending, be abandoned, and that public investment in public healthcare be increased;

Or. en
5.7.2023

**Amendment 68**
**Marc Botenga**
on behalf of The Left Group

**Report**
**Dolors Montserrat**
COVID-19 pandemic: lessons learned and recommendations for the future (2022/2076(INI))

**Motion for a resolution**
**Paragraph 586 a (new)**

<table>
<thead>
<tr>
<th>Motion for a resolution</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>586a. Calls on the Commission to promote an innovation ecosystem better set up for using collective intelligence to accelerate advances; highlights the need to use collective intelligence to accelerate advances, making wider use of open science, patent pools and compulsory licensing; calls on the Commission to support measures favouring open science in order to expedite the sharing of data and research results within the scientific community in Europe and beyond;</td>
<td></td>
</tr>
</tbody>
</table>

Or. en
5.7.2023 A9-0217/69

Amendment 69
Marc Botenga
on behalf of The Left Group

Report A9-0217/2023
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 586 b (new)

Motion for a resolution

586b. Calls for the introduction of a new incentive model, for decoupling mechanisms to be studied as an alternative to exclusive protection, and for strict conditions to be attached to the accessibility and availability of public funds for research and innovation, respecting the principle of a fair return on investment;

Amendment

Or. en
Amendment 70
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 614 a (new)

Motion for a resolution

614a. Calls for the EU Member States and the Commission to engage in proactive support for text-based negotiations on the extension of the MC12 TRIPS decision to therapeutics and diagnostics, and to accept that a more comprehensive TRIPS waiver than originally proposed at the WTO will be needed in the future to enhance equitable, universal and affordable access to critical medical countermeasures and to address possible global production constraints and supply shortages during pandemics;

Or. en